European CHMP Adopts Second Negative Opinion on Gamifant Authorization
uncategorized
The European Committee for Medicinal Products for Human Use (CHMP) has recommended the denial of market authorization for Gamifant (emapalumab) for the treatment of primary hemophagocytic lymphohistiocytosis (HLH) in children ... Read more